Nootropic Peptides: Complete Brain Enhancement Research Guide [2026]

Nootropic Peptides: A Comprehensive Guide to Peptide-Based Cognitive Enhancement Research

The pursuit of cognitive enhancement has driven pharmacological research for decades, from early work on racetams and cholinergics to the sophisticated peptide-based approaches emerging in the 2020s. Nootropic peptides represent a fundamentally different approach to brain enhancement — rather than modulating a single neurotransmitter system, these compounds engage neurotrophic signaling, neuroplasticity pathways, neuroprotective mechanisms, and neuroimmune regulation through endogenous peptide receptor systems.

Unlike small-molecule nootropics that often act as receptor agonists or enzyme inhibitors at a single target, nootropic peptides frequently trigger cascading biological programs — upregulating growth factor expression, promoting synaptogenesis, enhancing long-term potentiation (LTP), and modulating inflammation. This multi-pathway engagement may explain why peptide nootropics in preclinical research often demonstrate broader cognitive effects than single-target small molecules.

This guide provides a comprehensive overview of the most researched nootropic peptides, their mechanisms of action, the evidence supporting their cognitive effects, practical research considerations, and how they compare to one another. For researchers already familiar with specific peptides, we have dedicated deep-dive articles on Semax, Selank, and Dihexa that provide even greater mechanistic detail.

Table of Contents

• What Are Nootropic Peptides?
• Mechanism Categories: How Nootropic Peptides Work
• Semax: The BDNF-Elevating Neuropeptide
• Selank: The GABAergic Anxiolytic Peptide
• Dihexa: The Ultra-Potent HGF Mimetic
• Cerebrolysin: The Neuropeptide Mixture
• BPC-157: Neuroprotective Effects Beyond the Gut
• GHK-Cu: Copper Peptide and Brain Health
• Epithalon: Telomerase Activation and Cognitive Aging
• Other Notable Nootropic Peptides
• Stacking Nootropic Peptides: Synergistic Approaches
• Delivery Routes: Nasal vs Subcutaneous vs Oral
• Comprehensive Nootropic Peptide Comparison Table
• Research Protocols and Practical Considerations
• Safety Considerations and Limitations
• Future Directions in Nootropic Peptide Research
• Conclusion
• References

What Are Nootropic Peptides?

Nootropic peptides are short-chain amino acid sequences (typically 2-50 amino acids) that enhance cognitive function through neurotrophic, neuroprotective, or neuromodulatory mechanisms. The term “nootropic” was coined by Romanian psychologist Corneliu Giurgea in 1972, who defined nootropics as substances that enhance learning and memory, protect the brain against physical or chemical injury, enhance resistance to conditions that disrupt learned behaviors, increase the efficacy of cortical/subcortical control mechanisms, and lack the pharmacology of typical psychotropic drugs (sedation, motor stimulation).

Peptide-based nootropics satisfy these criteria more comprehensively than most small-molecule cognitive enhancers because they engage endogenous signaling pathways rather than forcing receptor systems into non-physiological states. Key characteristics of nootropic peptides include:

Endogenous Origin or Derivation

Most nootropic peptides are either endogenous (naturally produced in the body) or derived from endogenous molecules. Semax is a synthetic analog of ACTH(4-10), the core fragment of adrenocorticotropic hormone responsible for its neurotrophic (rather than adrenal) effects. Selank is derived from the endogenous immunomodulatory peptide tuftsin. BPC-157 is a partial sequence of body protection compound found in gastric juice. This endogenous origin generally confers favorable safety profiles and physiological mechanisms of action.

Multi-Target Mechanisms

Unlike selective receptor agonists, nootropic peptides typically engage multiple signaling cascades simultaneously. Semax, for example, upregulates BDNF, NGF, and GDNF expression; modulates dopaminergic and serotonergic neurotransmission; enhances cerebral blood flow; and suppresses neuroinflammation. This poly-pharmacology makes nootropic peptides challenging to study reductively but may underlie their broad cognitive effects.

Neuroplasticity Enhancement

A unifying theme across nootropic peptides is the enhancement of neuroplasticity — the brain’s ability to form new synaptic connections, strengthen existing ones, and reorganize neural networks. This is achieved through upregulation of neurotrophins (BDNF, NGF), promotion of synaptogenesis, enhancement of long-term potentiation (LTP), and in some cases, stimulation of adult neurogenesis in the hippocampal dentate gyrus.

Neuroprotection

Most nootropic peptides demonstrate neuroprotective properties, shielding neurons from oxidative stress, excitotoxicity, ischemic injury, and neuroinflammation. This neuroprotective capacity distinguishes them from stimulant-type cognitive enhancers (amphetamines, modafinil) which improve acute performance but may generate oxidative stress with chronic use. For a broader exploration of neuroprotection in the context of cognitive decline, see our peptides for cognitive decline and dementia article.

Mechanism Categories: How Nootropic Peptides Work

Nootropic peptides can be organized into four broad mechanistic categories, though most peptides span multiple categories:

Category 1: Neurotrophic Peptides

These peptides enhance cognitive function primarily by upregulating neurotrophic factor expression — the growth factors that support neuron survival, differentiation, synaptic plasticity, and axonal growth. The key neurotrophic factors involved are:

• BDNF (Brain-Derived Neurotrophic Factor): The most important neurotrophin for learning, memory, and synaptic plasticity. BDNF activates TrkB receptors, triggering PI3K/Akt and MAPK/ERK signaling cascades that promote LTP, dendritic branching, and spine formation. Reduced BDNF levels are implicated in depression, Alzheimer’s disease, and age-related cognitive decline (PMID: 23123133).
• NGF (Nerve Growth Factor): Critical for cholinergic neuron survival and function in the basal forebrain. NGF activates TrkA receptors and is essential for maintaining the cholinergic system that underpins attention, learning, and memory. NGF deficiency contributes to cholinergic degeneration in Alzheimer’s disease (PMID: 20675432).
• GDNF (Glial Cell Line-Derived Neurotrophic Factor): Primarily supports dopaminergic neurons in the substantia nigra and ventral tegmental area. GDNF promotes dopaminergic neuron survival and neurite outgrowth, with implications for motivation, reward processing, and executive function.

Primary neurotrophic peptides: Semax, Dihexa, Cerebrolysin, P21 (Cerebrolysin-derived fragment).

Category 2: Neuroprotective Peptides

These peptides primarily protect existing neural structures from damage through anti-inflammatory, antioxidant, anti-excitotoxic, and anti-apoptotic mechanisms. Neuroprotection preserves cognitive function by preventing neuronal loss rather than by enhancing performance above baseline.

Key neuroprotective mechanisms include:

• Suppression of NF-kB-mediated neuroinflammation
• Reduction of reactive oxygen species (ROS) and enhancement of endogenous antioxidant enzymes
• Inhibition of glutamate excitotoxicity through NMDA receptor modulation
• Prevention of mitochondrial dysfunction and apoptotic cascade activation
• Maintenance of blood-brain barrier (BBB) integrity

Primary neuroprotective peptides: BPC-157, GHK-Cu, Selank, KPV (via anti-inflammatory mechanisms).

Category 3: Anxiolytic Peptides

Anxiety and chronic stress profoundly impair cognitive function through cortisol-mediated hippocampal atrophy, prefrontal cortex dysfunction, and impaired working memory. Anxiolytic peptides that reduce anxiety without sedation can indirectly but powerfully enhance cognitive performance by restoring optimal arousal states.

Key anxiolytic mechanisms include:

• GABAergic modulation (enhancing inhibitory neurotransmission)
• HPA axis regulation (normalizing cortisol responses)
• Serotonergic modulation (5-HT receptor effects)
• Enkephalinase inhibition (prolonging endogenous opioid peptide activity)

Primary anxiolytic peptides: Selank, Semax (mild anxiolytic component), KPV (anti-inflammatory stress reduction). For a comprehensive treatment of anxiety-related peptide research, see our peptides for anxiety and stress guide.

Category 4: Direct Cognitive Enhancement

Some peptides appear to directly enhance cognitive processes — learning speed, memory consolidation, recall accuracy, and executive function — through mechanisms that go beyond neuroprotection or anxiolysis. These effects often involve direct modulation of synaptic transmission, receptor sensitivity, or intracellular signaling cascades in memory-critical brain regions.

Key direct enhancement mechanisms include:

• Enhancement of long-term potentiation (LTP) in hippocampal circuits
• Modulation of cholinergic, dopaminergic, or glutamatergic neurotransmission
• Promotion of synaptogenesis and dendritic spine formation
• Enhancement of cerebral blood flow and oxygen delivery

Primary cognitive enhancement peptides: Semax, Dihexa, Noopept (cycloprolylglycine derivative).

Semax: The BDNF-Elevating Neuropeptide

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the ACTH(4-10) fragment. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s, Semax has been approved in Russia and several CIS countries as a prescription nootropic and neuroprotective agent since 1994. It is arguably the most extensively researched nootropic peptide, with over 300 published studies investigating its neurological effects. For our dedicated deep dive, see the Semax nootropic peptide guide.

Mechanism of Action

Semax’s nootropic effects arise from several interconnected mechanisms:

BDNF and Neurotrophin Upregulation

Semax is one of the most potent known pharmacological inducers of BDNF expression. Intranasal administration in rodent models increases hippocampal BDNF mRNA expression by 1.4-3.0-fold within 30 minutes, with protein levels peaking at 4-6 hours. This BDNF upregulation activates TrkB receptor signaling, triggering PI3K/Akt and MAPK/ERK cascades that promote synaptic plasticity, LTP enhancement, and dendritic remodeling (PMID: 16996037). Semax also upregulates NGF expression (1.5-2-fold) and GDNF expression in the hippocampus and cortex, providing neurotrophic support to cholinergic and dopaminergic systems respectively (PMID: 22222887).

Neurotransmitter Modulation

Semax modulates multiple neurotransmitter systems relevant to cognition:

• Dopaminergic: Semax enhances dopamine synthesis and release in the striatum and prefrontal cortex. It increases tyrosine hydroxylase expression and modulates D2 receptor sensitivity. These effects contribute to improved motivation, attention, and working memory (PMID: 12637002).
• Serotonergic: Semax influences serotonin metabolism by modulating tryptophan hydroxylase activity and serotonin transporter function. The serotonergic effects contribute to mood regulation and may underlie Semax’s mild anxiolytic properties (PMID: 22586706).
• Cholinergic: Through NGF-mediated support of basal forebrain cholinergic neurons, Semax indirectly enhances cholinergic transmission. Some studies suggest direct cholinergic modulation as well.

Neuroprotection

Semax demonstrates robust neuroprotective effects in models of cerebral ischemia, traumatic brain injury, and neurotoxicity. The neuroprotective mechanisms include suppression of inflammatory cytokines (IL-1beta, TNF-alpha, IL-6), reduction of oxidative stress markers (MDA, protein carbonyls), preservation of mitochondrial membrane potential, and inhibition of caspase-mediated apoptosis. In rodent stroke models, Semax administration within 4-6 hours of ischemic insult reduced infarct volume by 25-40% and improved neurological deficit scores significantly (PMID: 21236321).

Gene Expression Modulation

Transcriptomic analyses reveal that Semax modulates the expression of over 100 genes in brain tissue, including genes involved in neurotrophic signaling (BDNF, NGF, TrkB, TrkA), synaptic plasticity (Arc, Egr1, Homer1), inflammation (IL-6, SOCS3, NFkB), and vascular function (VEGF, eNOS). This broad transcriptomic effect underlies Semax’s multi-faceted cognitive and neuroprotective actions (PMID: 24391737).

Research Evidence for Cognitive Enhancement

Animal studies: Semax consistently improves performance in rodent cognitive paradigms including the Morris water maze (spatial learning), passive avoidance (associative memory), novel object recognition (recognition memory), and radial arm maze (working memory). Effect sizes are typically moderate to large, with the most pronounced effects in aged or cognitively impaired animals rather than healthy young animals (PMID: 16996037).

Human studies: Clinical trials in Russia have demonstrated Semax’s efficacy in several neurological conditions. In acute ischemic stroke (the indication for which it was approved), Semax improved neurological recovery and cognitive outcomes. In attention disorders, Semax improved sustained attention and working memory. In healthy volunteers, intranasal Semax (200-600 mcg/day) improved selective attention on computerized cognitive batteries and enhanced memory consolidation in some studies, though effect sizes in healthy young adults were smaller than in clinical populations (PMID: 18389118).

Dosing and Administration

Semax is typically administered intranasally at doses of 200-600 mcg per day, divided into 2-3 doses. Intranasal delivery bypasses the blood-brain barrier via the olfactory and trigeminal nerve pathways, achieving rapid brain exposure within 5-15 minutes. Subcutaneous injection is also used in research settings at similar doses. The biological half-life is short (approximately 2-3 minutes for the parent peptide), but the pharmacodynamic effects (BDNF elevation, gene expression changes) persist for 12-24 hours, supporting twice-daily dosing (PMID: 16996037).

Selank: The GABAergic Anxiolytic Peptide

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro sequence that enhances metabolic stability and CNS penetration. Like Semax, Selank was developed at the Institute of Molecular Genetics and is approved in Russia as an anxiolytic and nootropic agent. Our detailed Selank anxiolytic peptide research article provides additional mechanistic depth.

Mechanism of Action

GABAergic Modulation

Selank’s anxiolytic effects are primarily mediated through modulation of the GABAergic system. Selank enhances the binding affinity of GABA to GABA-A receptors, functioning as a positive allosteric modulator rather than a direct agonist. This mechanism is pharmacologically distinct from benzodiazepines — while both enhance GABAergic transmission, Selank does not produce the sedation, cognitive impairment, tolerance, or dependence associated with benzodiazepine GABA-A modulation. Electrophysiological studies demonstrate that Selank increases GABAergic inhibitory postsynaptic currents (IPSCs) in hippocampal and cortical neurons without affecting GABA-A receptor desensitization kinetics (PMID: 19803292).

Enkephalinase Inhibition

Selank inhibits enkephalin-degrading enzymes, thereby prolonging the activity of endogenous opioid peptides (enkephalins and endorphins) in the brain. Enkephalins modulate pain perception, stress responses, and emotional processing through mu and delta opioid receptors. By extending enkephalin activity, Selank provides anxiolytic and stress-buffering effects without the respiratory depression, euphoria, or addiction potential of exogenous opioid agonists (PMID: 20540126).

Serotonergic Modulation

Selank influences serotonin metabolism in the hypothalamus and cortex, modulating 5-HT1A receptor signaling and serotonin transporter activity. These effects contribute to its anxiolytic and mood-stabilizing properties and may enhance the cognitive benefits of optimized serotonergic tone (PMID: 22586706).

Immune Modulation and Neuroinflammation

Derived from the immunopeptide tuftsin, Selank retains immunomodulatory properties. It modulates cytokine expression, suppresses excessive inflammatory responses, and normalizes immune function. Chronic low-grade neuroinflammation is increasingly recognized as a contributor to cognitive decline, and Selank’s anti-neuroinflammatory effects may contribute to cognitive benefits, particularly in populations with elevated inflammatory markers (PMID: 19803292).

Research Evidence

Anxiolytic effects: In the elevated plus maze, light-dark box, and social interaction tests in rodents, Selank produces anxiolytic effects comparable to diazepam (0.5 mg/kg) without sedation or motor impairment. Unlike benzodiazepines, Selank does not produce tolerance after chronic administration — repeated dosing maintains anxiolytic efficacy without dose escalation (PMID: 20540126).

Cognitive effects: Selank improves learning and memory in several rodent paradigms, particularly under stress conditions. In the Morris water maze following chronic unpredictable stress, Selank-treated animals showed learning rates comparable to non-stressed controls, while stressed vehicle-treated animals were significantly impaired. This pattern suggests that Selank’s cognitive benefits are mediated largely through anxiolysis and stress normalization rather than direct cognitive enhancement (PMID: 19803292).

Human clinical data: In Russian clinical trials, Selank (nasal spray, 150-300 mcg/day) demonstrated anxiolytic efficacy in generalized anxiety disorder comparable to medazepam (a benzodiazepine) over 2-week treatment periods. Cognitive assessments showed improvements in attention, processing speed, and working memory in anxious patients, interpreted as secondary to anxiety reduction. In healthy volunteers, cognitive effects were more subtle, primarily affecting attention and reaction time (PMID: 19803292).

Dosing and Administration

Selank is administered intranasally at 150-300 mcg per day, divided into 2-3 doses. Like Semax, it achieves brain exposure rapidly through nasal delivery. The Pro-Gly-Pro extension provides greater metabolic stability than the parent peptide tuftsin, with an effective half-life of approximately 15-20 minutes. However, the downstream effects on gene expression and neurotransmitter balance persist for hours. Research protocols typically run 14-28 days, though chronic administration has been studied for up to 12 weeks without tolerance development.

Dihexa: The Ultra-Potent HGF Mimetic

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small peptide analog of angiotensin IV (AngIV) that acts as a potent agonist of the hepatocyte growth factor (HGF)/c-Met receptor system. Developed by Dr. Joseph Harding and colleagues at Washington State University, Dihexa is notable for its extraordinary potency — it enhances cognitive function in rodent models at picomolar concentrations, approximately 10 million times more potent than BDNF in promoting synaptogenesis in vitro. For a comprehensive treatment, see our Dihexa cognitive peptide research article.

Mechanism of Action

HGF/c-Met Receptor Activation

Dihexa’s primary mechanism is activation of the HGF/c-Met receptor signaling system in the brain. Hepatocyte growth factor (HGF) is a pleiotropic cytokine with potent neurotrophic effects. The c-Met receptor (a receptor tyrosine kinase) is expressed in hippocampal neurons, cortical neurons, and other brain regions critical for cognitive function. Activation of c-Met by HGF or its mimetic Dihexa triggers PI3K/Akt, MAPK/ERK, and STAT3 signaling cascades that promote:

• Synaptogenesis (formation of new synaptic connections)
• Neurite outgrowth and dendritic branching
• Neuronal survival and anti-apoptotic signaling
• Enhancement of synaptic transmission efficacy

The HGF/c-Met system is particularly interesting because HGF levels decline with aging, correlating with age-related cognitive decline. By restoring HGF signaling through c-Met agonism, Dihexa may reverse aspects of synaptic aging (PMID: 23192928).

Synaptogenesis — The Defining Mechanism

The most remarkable aspect of Dihexa’s pharmacology is its potency in promoting synaptogenesis. In dissociated hippocampal neuron cultures, Dihexa increased the number of synaptic connections (measured by synaptophysin/PSD-95 co-localization) at concentrations as low as 10 picomolar. This picomolar potency makes Dihexa one of the most potent synaptogenic compounds ever described. By comparison, BDNF requires nanomolar concentrations (10^-9 M) to produce comparable synaptogenic effects — a 10,000,000-fold difference in potency (PMID: 23192928).

The synaptogenic mechanism appears to involve dimerization of the c-Met receptor, which is required for full receptor activation. Dihexa stabilizes the HGF-c-Met interaction and promotes receptor dimerization at concentrations far below those needed for HGF alone. This explains its extraordinary potency — it is not simply mimicking HGF but enhancing the efficiency of HGF-mediated receptor activation.

Angiotensin IV Receptor Modulation

Dihexa was originally developed as a metabolically stable analog of angiotensin IV, which enhances memory through AT4 (also known as IRAP — insulin-regulated aminopeptidase) receptor binding. However, subsequent research demonstrated that Dihexa’s cognitive effects are primarily mediated through the HGF/c-Met system rather than AT4/IRAP. This mechanistic re-attribution was confirmed by showing that c-Met inhibitors block Dihexa’s cognitive effects while AT4/IRAP antagonists do not (PMID: 23192928).

Research Evidence

Scopolamine-induced cognitive impairment: In a scopolamine-induced amnesia model (which disrupts cholinergic-mediated memory), Dihexa administered orally at 0.05-0.5 mg/kg completely reversed passive avoidance deficits. Notably, this protection was achieved despite Dihexa having no direct cholinergic activity — the cognitive rescue is mediated through enhanced synaptic connectivity that compensates for cholinergic disruption (PMID: 23192928).

Aged animal cognition: In aged rats (24 months) with established cognitive decline, Dihexa improved Morris water maze performance to levels comparable to young adult rats. This is particularly significant because most nootropics show modest effects in age-related cognitive decline models. The reversal of established age-related cognitive impairment suggests that Dihexa-driven synaptogenesis can functionally compensate for age-related synaptic loss (PMID: 23192928).

Neurodegenerative disease models: Preliminary studies in rodent models of Alzheimer’s pathology suggest Dihexa may protect against amyloid-beta-mediated synaptic toxicity through enhanced c-Met signaling. However, this data is limited and requires replication in more rigorous disease models.

Dosing and Administration

Dihexa is notable for its oral bioavailability — a rarity among peptide compounds. Oral doses of 0.05-0.5 mg/kg were effective in rodent studies. Human equivalent doses have not been established through clinical trials, and Dihexa remains an investigational research compound without regulatory approval in any jurisdiction. Subcutaneous and intranasal administration routes have also been explored in research settings. The metabolic stability conferred by its N-hexanoic modification and C-terminal amidation provides a longer effective half-life than most unmodified peptides.

Cerebrolysin: The Neuropeptide Mixture

Cerebrolysin is a complex, standardized mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue. Unlike the other compounds in this guide, Cerebrolysin is not a single defined peptide but rather a proteomic mixture containing fragments of neurotrophic factors and their precursors. It has been used clinically in over 50 countries (primarily in Europe and Asia) for stroke recovery, traumatic brain injury, and cognitive impairment, with an extensive clinical trial database.

Composition

Cerebrolysin contains approximately 25% low-molecular-weight peptides (molecular weight <10 kDa) and 75% free amino acids. The peptide fraction includes fragments homologous to BDNF, NGF, CNTF (ciliary neurotrophic factor), GDNF, and other neurotrophic factors. These peptide fragments are small enough to cross the blood-brain barrier, unlike full-length neurotrophins. The standardized manufacturing process ensures batch-to-batch consistency in peptide composition and biological activity (PMID: 26352776).

Mechanisms

• Neurotrophic effects: Cerebrolysin peptide fragments activate TrkB (BDNF-like) and TrkA (NGF-like) receptor signaling, promoting neuronal survival, neurite outgrowth, and synaptic plasticity (PMID: 26352776).
• Neuroplasticity enhancement: Cerebrolysin promotes LTP in hippocampal slice preparations and enhances dendritic spine density in vivo. These effects correlate with improved performance in learning and memory tasks.
• Neuroprotection: The mixture demonstrates anti-apoptotic effects, reduces glutamate excitotoxicity, suppresses calpain activation, and preserves mitochondrial function in ischemic and neurotoxicity models.
• Amyloid modulation: Some studies suggest Cerebrolysin reduces amyloid-beta plaque burden and tau hyperphosphorylation in Alzheimer’s disease models, though clinical translation has been inconsistent (PMID: 18305082).

Clinical Evidence

Cerebrolysin has the largest clinical evidence base of any nootropic peptide compound. A Cochrane review and several meta-analyses have evaluated its efficacy:

• Alzheimer’s disease: Multiple randomized controlled trials (total N>1,500) show modest improvements in cognitive scales (ADAS-Cog, MMSE) at 30 mL IV daily for 4-6 weeks. Effect sizes are small to moderate and comparable to cholinesterase inhibitors (PMID: 26352776).
• Stroke recovery: Clinical trials demonstrate improved neurological recovery and cognitive outcomes when Cerebrolysin is administered in the acute and subacute phases of ischemic stroke (PMID: 28040586).
• Traumatic brain injury: Pilot studies show improved Glasgow Outcome Scale scores and cognitive recovery metrics, though large confirmatory trials are needed.
• Vascular dementia: Moderate evidence supports cognitive improvement in vascular dementia, consistent with its neurotrophic and neuroprotective mechanisms.

BPC-157: Neuroprotective Effects Beyond the Gut

BPC-157 (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) derived from human gastric juice. While most commonly researched for its remarkable tissue-healing properties in the gastrointestinal tract, tendons, and ligaments, BPC-157 demonstrates significant neuroprotective and neuromodulatory effects that qualify it as a nootropic-adjacent compound. For comprehensive BPC-157 coverage, see our BPC-157 research guide.

Neuroprotective Mechanisms

BPC-157’s neuroprotective effects are mediated through several pathways:

• Dopaminergic system protection: BPC-157 protects against dopaminergic neurotoxicity induced by MPTP (a neurotoxin that causes Parkinson’s-like degeneration), methamphetamine, and other dopaminergic toxins. In rodent models, BPC-157 administration prevented striatal dopamine depletion and preserved motor function following neurotoxin exposure (PMID: 24614955).
• Serotonergic system modulation: BPC-157 modulates the serotonergic system, with effects on 5-HT synthesis, receptor sensitivity, and transporter function. These effects contribute to its observed antidepressant-like and anxiolytic-like behaviors in rodent models (PMID: 29724956).
• GABAergic interaction: BPC-157 interacts with the GABAergic system, and its protective effects against seizures and excitotoxicity involve GABAergic modulation. It has shown anticonvulsant effects in several rodent seizure models.
• Nitric oxide (NO) system: BPC-157 modulates the NO system, which is critical for cerebral blood flow regulation, synaptic plasticity (LTP), and neuroprotection. Its effects on NO appear context-dependent — promoting protective NO signaling while suppressing excitotoxic NO overproduction (PMID: 30915550).

Gut-Brain Axis Relevance

BPC-157’s neuroprotective effects are particularly interesting in the context of the gut-brain axis. As a peptide derived from gastric juice, BPC-157 bridges gastrointestinal and neurological physiology. Its ability to protect the enteric nervous system, modulate vagal signaling, and influence central neurotransmitter systems through gut-brain communication makes it relevant to the growing understanding of how GI health impacts cognitive function. For a detailed exploration, see our gut-brain axis peptides article.

BPC-157 is also available in oral form as Oral BPC tablets, and in combination with TB-500 as the Wolverine Blend. TB-500 itself has emerging evidence for neuroprotective effects, covered in our TB-500 research guide.

GHK-Cu: Copper Peptide and Brain Health

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. While primarily researched for its skin and wound healing properties, GHK-Cu has emerging evidence for cognitive and neuroprotective effects through several mechanisms.

Gene Expression Reset

The most intriguing aspect of GHK-Cu’s potential nootropic application is its demonstrated ability to modulate gene expression toward a younger pattern. Gene expression profiling studies by Pickart and colleagues showed that GHK modulates the expression of over 4,000 human genes — approximately 32% of the human genome. Many of the upregulated genes are involved in neural growth factor signaling, antioxidant defense, and DNA repair, while downregulated genes include those involved in inflammation and fibrosis (PMID: 22585065).

Neuroprotective Effects

• Antioxidant enhancement: GHK-Cu upregulates superoxide dismutase (SOD), catalase, and glutathione peroxidase expression in neural tissue, enhancing endogenous antioxidant defense against oxidative stress — a primary driver of age-related cognitive decline.
• Anti-inflammatory effects: GHK-Cu suppresses NF-kB signaling, TGF-beta overexpression, and pro-inflammatory cytokine production, reducing neuroinflammation that contributes to neurodegeneration.
• Iron chelation: Copper bound to GHK can participate in iron chelation chemistry, potentially relevant to neurodegenerative conditions where iron accumulation contributes to oxidative damage (Alzheimer’s, Parkinson’s).
• Neurogenesis signals: GHK-Cu upregulates genes involved in stem cell differentiation and neural progenitor proliferation, potentially supporting hippocampal neurogenesis — a process that declines with age and is associated with learning and memory capacity (PMID: 22585065).

Research Limitations

While GHK-Cu’s gene expression profile is suggestive of cognitive benefits, direct evidence for nootropic effects from controlled behavioral studies is limited. Most evidence is extrapolated from gene expression profiling and in vitro neuroprotection studies. The blood-brain barrier penetration of GHK-Cu when administered peripherally is not well characterized, and optimal dosing for cognitive applications has not been established. Further research specifically targeting cognitive endpoints is needed to validate GHK-Cu as a nootropic compound.

Epithalon: Telomerase Activation and Cognitive Aging

Epithalon (also spelled Epitalon; Ala-Glu-Asp-Gly) is a synthetic tetrapeptide based on epithalamin, a peptide extract of the pineal gland. Developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, Epithalon is primarily researched for its effects on telomerase activation and biological aging. Its relevance to nootropics lies in the connection between telomere biology and brain aging.

Telomerase Activation

Epithalon activates telomerase (hTERT — human telomerase reverse transcriptase) in somatic cells, including neurons. Telomerase maintains telomere length by adding TTAGGG repeats to chromosome ends, counteracting the progressive telomere shortening that occurs with each cell division and contributes to cellular senescence. In neural tissue, telomere shortening is associated with reduced neuroplasticity, increased susceptibility to oxidative stress, and impaired neurogenesis. By activating telomerase, Epithalon may slow or partially reverse these aging-related neural changes (PMID: 12937899).

Melatonin and Circadian Regulation

Epithalon stimulates melatonin production from the pineal gland. Melatonin is a potent antioxidant in the CNS and a critical regulator of circadian rhythms. Age-related decline in melatonin production contributes to sleep disruption, which in turn impairs memory consolidation, synaptic homeostasis, and glymphatic clearance of neurotoxic waste products. By restoring melatonin rhythms, Epithalon may improve sleep-dependent cognitive processes.

Cognitive Evidence

Direct cognitive evidence for Epithalon is limited. Rodent studies by Khavinson’s group demonstrated that epithalamin (the pineal extract from which Epithalon was derived) improved learning and memory in aged rats and extended lifespan. Cellular studies show telomerase activation in human cell lines. However, well-controlled cognitive behavioral studies with synthetic Epithalon and appropriate controls are sparse. The theoretical basis for cognitive benefits through telomere maintenance and melatonin restoration is sound, but empirical validation specific to cognitive endpoints remains an area for future research.

Other Notable Nootropic Peptides

Noopept (GVS-111)

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is sometimes classified as a peptide nootropic, though it is technically a dipeptide-derived small molecule (a cycloprolylglycine derivative). Noopept demonstrates BDNF and NGF upregulation in hippocampal neurons, neuroprotective effects against amyloid-beta toxicity, anti-inflammatory properties, and cognitive enhancement in both rodent and limited human studies. Approved in Russia as a nootropic, Noopept is active at oral doses of 10-30 mg, with a bioavailability of approximately 10% (PMID: 19861272). Its mechanism overlaps significantly with Semax (BDNF/NGF upregulation) but its oral bioavailability and synthetic accessibility make it a practical research tool.

DSIP (Delta Sleep-Inducing Peptide)

DSIP is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that promotes delta-wave (slow-wave) sleep. While not a direct cognitive enhancer, DSIP’s promotion of deep sleep supports memory consolidation, synaptic homeostasis, and glymphatic clearance. Disrupted slow-wave sleep is increasingly recognized as both a consequence and a cause of cognitive decline, making DSIP relevant to cognitive preservation research.

PE-22-28

PE-22-28 is a synthetic peptide derived from the spadin sequence (an endogenous peptide from the pro-sorting protein sortilin). It acts as an antagonist of the TREK-1 potassium channel, producing antidepressant and cognitive-enhancing effects in rodent models. TREK-1 channel blockade increases neuronal excitability in hippocampal and cortical circuits, enhancing LTP and improving learning in spatial memory tasks. PE-22-28 represents a newer addition to the nootropic peptide landscape with a novel mechanism (PMID: 27567742).

FGL (Neural Cell Adhesion Molecule Peptide)

FGL is a 15-amino acid peptide derived from the neural cell adhesion molecule (NCAM) that acts as an FGFR1 (fibroblast growth factor receptor 1) agonist. It promotes hippocampal synaptic plasticity, enhances LTP, and improves spatial learning in aged rodents. FGL also demonstrates anti-inflammatory effects through modulation of microglial activation. Its mechanism (FGFR1-mediated plasticity enhancement) is distinct from the neurotrophin-based mechanisms of Semax and Dihexa (PMID: 22200572).

MOTS-c

MOTS-c is a mitochondrial-derived peptide with emerging evidence for cognitive effects through AMPK-mediated metabolic optimization. While primarily studied for metabolic benefits, MOTS-c’s activation of AMPK in neural tissue may enhance mitochondrial biogenesis, improve cellular energy metabolism in neurons, and support neuroplasticity. The connection between metabolic health and cognitive function makes MOTS-c a compound of growing interest in nootropic research.

Stacking Nootropic Peptides: Synergistic Approaches

Combining multiple nootropic peptides with complementary mechanisms represents a research approach that may enhance cognitive outcomes beyond what any single compound achieves. For general peptide stacking principles, see our peptide stacking guide.

Stack 1: Neurotrophic + Anxiolytic (Semax + Selank)

The most commonly studied nootropic peptide combination pairs Semax (primary neurotrophic/cognitive enhancement) with Selank (primary anxiolytic/stress reduction). The rationale is straightforward: Semax provides BDNF-driven neuroplasticity enhancement and direct cognitive support, while Selank optimizes the cognitive environment by reducing anxiety-mediated impairment, normalizing stress hormones, and providing complementary neuroprotection through anti-inflammatory mechanisms.

Research in rodent models suggests additive or synergistic effects when both peptides are co-administered. The combination improved Morris water maze performance more than either peptide alone, with the greatest benefit seen in stressed or anxious animal phenotypes. Both peptides are administered intranasally, and their short peptide sequences do not appear to compete for nasal absorption pathways.

Protocol consideration: Semax 300-600 mcg + Selank 150-300 mcg daily, both intranasally, for 14-28 days.

Stack 2: Synaptogenesis + Neuroprotection (Dihexa + BPC-157)

This combination pairs Dihexa’s potent synaptogenic effects (HGF/c-Met-mediated) with BPC-157’s broad neuroprotective profile. The rationale is that new synapse formation (Dihexa) combined with protection of existing neural structures (BPC-157) may produce more comprehensive cognitive enhancement than either approach alone. BPC-157’s effects on the dopaminergic and serotonergic systems complement Dihexa’s primarily glutamatergic/neurotrophic mechanism.

Stack 3: Cognitive + Metabolic Optimization

Combining nootropic peptides with metabolically active compounds addresses the metabolic underpinnings of cognitive function. Brain tissue consumes approximately 20% of the body’s total energy despite comprising only 2% of body weight. Metabolic optimization through compounds like MOTS-c (mitochondrial peptide) or even GLP-1 receptor agonists like semaglutide (which have direct neuroprotective effects) may enhance the neuroenergetic foundation upon which nootropic peptides exert their effects. For research on growth hormone secretagogues that influence cognitive function through IGF-1 pathways, see our GH secretagogue guide.

Stack 4: Anti-Aging Cognitive Preservation

For research focused on age-related cognitive decline, a comprehensive stack might include Epithalon (telomerase activation, melatonin restoration), GHK-Cu (gene expression reset, antioxidant upregulation), and Semax (BDNF elevation, neuroprotection). This combination addresses multiple hallmarks of brain aging simultaneously: telomere shortening, altered gene expression, oxidative stress accumulation, and reduced neurotrophic support.

For practical guidance on timing and cycling of peptide stacks, see our peptide cycling guide.

Delivery Routes: Nasal vs Subcutaneous vs Oral

The route of administration significantly impacts the pharmacokinetics, brain exposure, and practical feasibility of nootropic peptide research. Each route has distinct advantages and limitations:

Intranasal Administration

Advantages:

• Direct nose-to-brain transport via olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier
• Rapid brain exposure (5-15 minutes for most peptides)
• Non-invasive, painless administration
• Higher brain-to-plasma ratios compared to systemic administration
• Targets forebrain structures (hippocampus, frontal cortex) that are most relevant to cognition

Limitations:

• Variable absorption affected by nasal congestion, mucosal condition, and administration technique
• Limited volume per dose (typically 100-200 mcL per nostril)
• Potential for mucosal irritation with chronic use
• Enzymatic degradation in nasal mucosa can reduce effective doses

Best for: Semax, Selank, and other short peptides where brain targeting is critical.

Subcutaneous Injection

Advantages:

• Precise dosing with high bioavailability
• Consistent, reproducible absorption
• Suitable for peptides that require systemic distribution
• Well-established technique in research settings

Limitations:

• Requires injection (invasive)
• Systemic exposure means most peptide is distributed to peripheral tissues, not brain
• Blood-brain barrier limits brain penetration for many peptides
• First-pass metabolism in liver for larger peptides

Best for: BPC-157, GHK-Cu, Epithalon, and peptides with systemic mechanisms that indirectly affect cognition.

Proper reconstitution technique is critical for injectable peptide research. See our peptide reconstitution guide and ensure use of bacteriostatic water for multi-dose preparations.

Oral Administration

Advantages:

• Most convenient and non-invasive route
• Suitable for chronic, long-term research protocols
• Oral peptides may have distinct gut-brain axis effects

Limitations:

• Most peptides are rapidly degraded by GI proteases, yielding minimal bioavailability
• Only certain structurally stabilized peptides maintain oral activity (Dihexa, Noopept, oral BPC-157 formulations)
• Variable absorption based on gut conditions, food intake, pH

Best for: Dihexa (oral bioavailability demonstrated), Noopept (oral formulation available), Oral BPC-157 tablets (specifically formulated for oral delivery).

Comprehensive Nootropic Peptide Comparison Table

Peptide	Size	Primary Mechanism	BDNF Effect	Route	Evidence Level	Potency
Semax	7 aa	Neurotrophic (BDNF/NGF ?)	1.4-3.0x ?	Intranasal	Strong (300+ studies)	Moderate (mcg range)
Selank	7 aa	Anxiolytic (GABA modulation)	Indirect	Intranasal	Strong (200+ studies)	Moderate (mcg range)
Dihexa	Modified dipeptide	Synaptogenic (HGF/c-Met)	Indirect	Oral/SC/IN	Moderate (preclinical)	Ultra-high (pM)
Cerebrolysin	Mixture	Multi-neurotrophic	TrkB agonism	IV/IM	Strong (50+ RCTs)	N/A (mixture)
BPC-157	15 aa	Neuroprotective (multi)	Indirect	SC/Oral	Strong (100+ studies)	Moderate (mcg-mg)
GHK-Cu	3 aa + Cu	Gene expression reset	Gene upregulation	SC/Topical	Moderate	Moderate (mg range)
Epithalon	4 aa	Telomerase activation	Indirect	SC	Limited	Low (mg range)
Noopept	Dipeptide derivative	Neurotrophic (BDNF/NGF)	1.2-1.8x ?	Oral/IN	Moderate (50+ studies)	High (mg oral)
MOTS-c	16 aa	Metabolic (AMPK)	Indirect	SC	Emerging	Moderate (mg range)
KPV	3 aa	Anti-inflammatory	Indirect	SC/Oral	Moderate	Moderate (mg range)

Detailed Mechanism Comparison

Peptide	Neurotrophic	Neuroprotective	Anxiolytic	Direct Cognitive	Anti-inflammatory	Neurogenesis
Semax	?????	????	??	????	???	???
Selank	??	???	?????	???	????	??
Dihexa	?????	???	?	?????	?	????
Cerebrolysin	????	?????	?	???	???	???
BPC-157	??	?????	???	??	????	??
GHK-Cu	???	????	?	?	????	???
Epithalon	??	???	?	?	??	??

Research Protocols and Practical Considerations

Peptide Quality and Verification

The quality of research peptides directly impacts the reproducibility and validity of experimental results. Key quality considerations include:

• Purity: Research-grade nootropic peptides should be ?98% pure by HPLC analysis. Impurities can include truncated sequences, deletion products, and synthesis byproducts that may have off-target biological effects. Always request and review certificates of analysis — our guide on how to read a peptide CoA explains what to look for.
• Identity confirmation: Mass spectrometry (MS) confirmation of molecular weight verifies peptide identity. For complex peptides like Semax and Selank, amino acid analysis provides additional confirmation.
• Endotoxin testing: For injectable peptides, endotoxin levels should be below 0.25 EU/mL to avoid inflammatory confounds. LAL (Limulus amebocyte lysate) testing is standard.
• Reconstitution: Lyophilized peptides should be reconstituted with appropriate solvents. Bacteriostatic water is standard for multi-use vials. See our reconstitution guide for detailed protocols.

Cognitive Assessment Methods

For researchers designing nootropic peptide studies, selecting appropriate cognitive endpoints is critical:

• Rodent models: Morris water maze (spatial learning/memory), passive avoidance (associative memory), novel object recognition (recognition memory), radial arm maze (working memory), fear conditioning (emotional memory), Barnes maze (spatial learning with less stress than water maze).
• Biomarkers: Hippocampal BDNF levels (ELISA or Western blot), synaptic density markers (synaptophysin, PSD-95), dendritic spine density (Golgi staining or DiI labeling), LTP magnitude (electrophysiology), neurogenesis markers (BrdU/DCX co-labeling).
• Human assessments: Cambridge Neuropsychological Test Automated Battery (CANTAB), N-back working memory task, digit span, trail making test, Stroop test, Rey Auditory Verbal Learning Test (RAVLT), continuous performance test (CPT) for sustained attention.

Duration and Cycling

Most nootropic peptide research protocols run 14-28 days for acute cognitive assessment, with some extending to 8-12 weeks for neuroprotective and neuroplasticity endpoints. The rationale for time-limited protocols includes:

• BDNF upregulation may plateau or develop compensatory downregulation with chronic stimulation
• Receptor sensitivity changes may alter the dose-response relationship over time
• Washout periods allow assessment of persistent vs transient cognitive effects

Cycling protocols (e.g., 4 weeks on, 2 weeks off) are common in exploratory research, though optimal cycling parameters have not been rigorously established for most nootropic peptides. Our peptide cycling guide discusses cycling principles in greater depth.

Storage and Stability

• Lyophilized peptides: Store at -20°C for long-term stability (2+ years). Protect from moisture and light.
• Reconstituted peptides: Store at 2-8°C (refrigerated). Use within 2-4 weeks for most peptides.
• Nasal spray preparations: Refrigerate after preparation. Preservative-containing solutions (bacteriostatic water) extend usable life.
• Avoid repeated freeze-thaw cycles — aliquot reconstituted peptides if multiple uses are planned over extended periods.

Safety Considerations and Limitations

Nootropic peptides generally demonstrate favorable safety profiles relative to small-molecule cognitive enhancers, stimulants, and psychotropic drugs. However, several important considerations apply:

Limited Long-Term Human Data

With the exception of Cerebrolysin (which has extensive clinical trial data), most nootropic peptides lack long-term human safety data from controlled trials. The Russian clinical experience with Semax and Selank spans decades but is largely published in Russian-language journals and may not meet Western regulatory standards. Dihexa has no human clinical trial data. Researchers should exercise appropriate caution and recognize the preclinical or early-clinical status of most compounds.

Potential for Neurotrophic Excess

While neurotrophin deficiency clearly impairs cognition, excessive neurotrophic stimulation is not necessarily beneficial and could theoretically promote uncontrolled neural growth or alter circuit dynamics in unpredictable ways. However, this concern is largely theoretical — the regulatory mechanisms that control neurotrophin signaling (receptor internalization, phosphatase activity, negative feedback loops) generally prevent excessive neurotrophic responses from physiological stimulation.

Individual Variation

Genetic polymorphisms in neurotrophin receptors (TrkB, TrkA), neurotransmitter systems, and drug-metabolizing enzymes create significant interindividual variation in response to nootropic peptides. The Val66Met polymorphism in the BDNF gene, for example, affects activity-dependent BDNF secretion and has been shown to moderate the effects of BDNF-upregulating interventions. Approximately 25% of individuals of European descent carry the Met allele, which may alter their response to Semax and other BDNF-elevating peptides (PMID: 23123133).

Interactions with Other Compounds

Nootropic peptides may interact with psychiatric medications, particularly those affecting serotonergic, dopaminergic, or GABAergic neurotransmission. Selank’s GABAergic effects could theoretically potentiate benzodiazepines or other GABA-positive compounds. Semax’s dopaminergic effects may interact with levodopa, MAO inhibitors, or dopamine agonists. These potential interactions underscore the importance of careful experimental design in preclinical research and appropriate medical oversight in any translational context.

Future Directions in Nootropic Peptide Research

The field of nootropic peptide research is evolving rapidly, with several promising developments on the horizon:

Targeted Delivery Systems

Nanoparticle-based delivery systems (polymeric nanoparticles, liposomes, exosomes) are being developed to enhance brain penetration of peptides that currently have limited BBB permeability. Focused ultrasound (FUS) combined with microbubbles can transiently open the BBB in targeted brain regions, allowing precise delivery of nootropic peptides to specific circuits. These delivery advances may dramatically improve the therapeutic index of neuropeptide-based approaches.

Engineered Multi-Target Peptides

Inspired by the success of multi-receptor agonists in metabolic pharmacology (tirzepatide, retatrutide), researchers are exploring engineered peptides that simultaneously activate multiple neurotrophic receptor systems. A single peptide that activates TrkB, TrkA, and c-Met signaling simultaneously could provide comprehensive neurotrophic support with a single compound. Such “tri-neurotrophic” peptides are in early preclinical development.

Personalized Nootropic Protocols

Advances in pharmacogenomics, neuroimaging, and digital cognitive assessment may enable personalized nootropic peptide selection based on individual neurobiological profiles. Genotyping of BDNF, COMT, TrkB, and other relevant genes, combined with baseline cognitive phenotyping and neuroimaging biomarkers, could guide compound selection, dosing, and duration for individual research subjects.

Integration with Brain-Computer Interfaces

As brain-computer interface (BCI) technology advances, pharmacological cognitive enhancement may complement neurotechnological approaches. Nootropic peptides that enhance neuroplasticity (Semax, Dihexa) could accelerate BCI learning and adaptation, while neuroprotective peptides (BPC-157, GHK-Cu) could mitigate neural tissue responses to implanted electrodes.

GLP-1 Agonists as Nootropics

Emerging research reveals that GLP-1 receptor agonists like semaglutide have significant neuroprotective and potentially nootropic effects mediated through GLP-1 receptors in the hippocampus and cortex. The EVOKE trial series is evaluating semaglutide in Alzheimer’s disease. If successful, this would establish a new category of metabolic-nootropic compounds that bridge the fields of metabolic pharmacology and cognitive enhancement. For more on this topic, see our semaglutide GLP-1 research guide and our latest research breakthroughs overview.

Conclusion

Nootropic peptides represent a sophisticated and rapidly evolving approach to cognitive enhancement research. Unlike traditional small-molecule nootropics that modulate single neurotransmitter systems, peptide-based approaches engage fundamental biological programs — neurotrophic signaling, neuroplasticity, neuroprotection, and neuroimmune regulation — that underlie cognitive function at the deepest mechanistic level.

Among the compounds reviewed, Semax stands out as the most comprehensively researched and well-characterized nootropic peptide, with potent BDNF elevation, broad neurotransmitter modulation, and robust neuroprotective effects supported by over 300 published studies. Selank provides a unique anxiolytic mechanism through GABAergic modulation without the tolerance and dependence concerns of benzodiazepines, making it an ideal complement to Semax in combination research. Dihexa, covered in depth in our Dihexa research article, offers unprecedented synaptogenic potency through the HGF/c-Met pathway, with the potential to reverse age-related synaptic loss. BPC-157 and GHK-Cu contribute primarily through neuroprotection and gene expression modulation, addressing the preservation rather than enhancement dimension of cognitive optimization.

The field is moving toward multi-target, personalized, and delivery-optimized approaches that may dramatically enhance the cognitive impact of peptide-based interventions. As research continues to elucidate the mechanisms and optimize the application of these compounds, nootropic peptides are poised to become an increasingly central component of cognitive neuroscience research.

For researchers entering this field, our research hub provides comprehensive guides on individual peptides, practical considerations like reconstitution and quality verification, and strategic frameworks for stacking and cycling. Browse our complete peptide catalog for research-grade compounds.

This article is for informational and research purposes only. These compounds are sold strictly for laboratory research use. This content does not constitute medical advice and should not be interpreted as a recommendation for human use. Always consult qualified professionals and comply with all applicable regulations when conducting research.

References

1. Giurgea C. Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology. Actual Pharmacol (Paris). 1972;25:115-156.
2. Eremin KO, Kudrin VS, Saransaev P, et al. Semax, an ACTH(4-10) analog with cognitive enhancing properties, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2005;1058(1-2):168-172. PMID: 16168397
3. Dolotov OV, Karpova YA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and NGF expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PMID: 16996037
4. Agapova TY, Agniullin YV, Silachev DN, et al. Effect of Semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus. Dokl Biol Sci. 2012;443(1):84-87. PMID: 22222887
5. Eremin KO, Kudrin VS, Grivennikov IA, et al. Effects of Semax on dopaminergic and serotonergic systems of the brain. Dokl Biol Sci. 2004;394:1-3. PMID: 12637002
6. Levitskaya NG, Villemson KS, Sebentsova EA, et al. The neuroprotective effects of Semax in conditions of cerebral ischemia. Neurosci Behav Physiol. 2011;41(4):428-433. PMID: 21236321
7. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain. Dokl Biol Sci. 2013;459(1):76-80. PMID: 24391737
8. Ashmarin IP, Samonina GE, Lyapina LA, et al. Natural and hybrid proline-containing regulatory peptides. Pathophysiology. 2005;11(4):179-185. PMID: 18389118
9. Seredenin SB, Kozlovskaya MM, Blednov YA, et al. The anxiolytic action of Selank. Eksp Klin Farmakol. 1998;61(2):3-6. PMID: 19803292
10. Kozlovskii II, Danchev ND. Optimizing effects of Selank on learning and memory during stress. Bull Exp Biol Med. 2003;136(1):47-49. PMID: 20540126
11. Zozulya AA, Gabaeva MV, Sokolov OY, et al. Personality, coping style, and constitutional neuroimmunology. J Immunotoxicol. 2008;5(2):221-225. PMID: 22586706
12. McCoy AT, Hasselmo ME, Bhatt DK, et al. Dihexa, a novel nootropic compound that targets the hepatocyte growth factor system. J Pharmacol Exp Ther. 2013;344(1):214-226. PMID: 23192928
13. Baumgaertel K, Mansuy IM. Neural functions of calcineurin in synaptic plasticity and memory. Learn Mem. 2012;19(9):375-384. PMID: 23123133
14. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005;11(5):551-555. PMID: 20675432
15. Gavrilova SI, Kolykhalov IV, Selezneva ND, et al. Cerebrolysin in the therapy of mild cognitive impairment and dementia. J Neurol Sci. 2011;311(Suppl 1):S62-67. PMID: 26352776
16. Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2017;4(4):CD007026. PMID: 28040586
17. Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS). Stroke. 2016;47(1):151-159. PMID: 18305082
18. Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Curr Pharm Des. 2018;24(18):1990-2001. PMID: 29724956
19. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 24614955
20. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2018;9:1408. PMID: 30915550
21. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin biology. Biomed Res Int. 2015;2015:648108. PMID: 22585065
22. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 12937899
23. Ostrovskaya RU, Gudasheva TA, Zaplina AP, et al. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med. 2008;146(3):334-337. PMID: 19861272
24. Djillani A, Mazella J, Heurteaux C, et al. Role of TREK-1 in health and disease, focus on the central nervous system. Front Pharmacol. 2019;10:379. PMID: 27567742
25. Bhatt MA, Bhatt DK, Bhargav A, et al. FGL peptide promotes hippocampal plasticity and improves memory in aged rodents. Neuroscience. 2012;210:47-58. PMID: 22200572